Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

NCT00717925 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell

Interventions

DRUG: Inotuzumab Ozogamicin (CMC-544)

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer